Front Immunol. 2025 Oct 2;16:1673098. doi: 10.3389/fimmu.2025.1673098. eCollection 2025.

ABSTRACT

INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) continues to exhibit resistance to immunotherapy. In this study, we evaluated the efficacy of combining immunotherapy with chemotherapy for the treatment of advanced pancreatic cancer. Additionally, we employed a multimodal analytical approach to elucidate the immune landscape and conduct transcriptomic profiling in PDAC.

METHODS: A retrospective analysis was conducted on the clinical data of 52 patients diagnosed with advanced PDAC who underwent a combined treatment regimen of immunotherapy and chemotherapy. The study evaluated the objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS). To characterize the immune landscape in treatment-naive pancreatic ductal adenocarcinoma (PDAC) tumors and in the systemic circulation, flow cytometry, multiplex immunohistochemistry (mIHC), and whole transcriptome sequencing were employed.

RESULTS: The study reported an ORR of 32.7%, a DCR of 67.3%, and a 6-month PFS rate of 38.5%, with a median PFS of 5.5 months. Patients treated with a combination of immunotherapy and gemcitabine achieved the longest PFS. The first-line treatment cohort exhibited a significantly higher DCR (79.3% vs. 52.2%, P = 0.038) and a longer median PFS (6.6 vs. 3.5 months, P = 0.032) compared to the second-line treatment cohort. The efficacy of treatment varied depending on the drug combinations used. Flow cytometry analysis revealed a greater frequency of CD45- CD64+ cells in the peripheral blood of patients with progressive disease (PD) compared to those with a partial response (PR). Multiplex immunofluorescence (MIF) analysis indicated an increased intratumoral infiltration of CD8+ T cells and CD137+ CD8+ T cells in patients with PR. Whole transcriptome sequencing (WTSS) identified key genes involved in immune regulation, signal transduction, and digestive function. Hemopexin (HPX) and regulatory factor X-associated protein (RFXAP) were upregulated in PR patients and showed a positive correlation with survival, whereas Interleukin-6 (IL-6) expression was linked to poor prognosis.

CONCLUSIONS: These findings indicate that immunochemotherapy shows potential for the treatment of advanced PDAC. Our study elucidates the immune landscape associated with PDAC and provides critical insights for the identification of prospective therapeutic targets, which could guide the development of innovative combination immunotherapy strategies.

PMID:41112307 | PMC:PMC12528169 | DOI:10.3389/fimmu.2025.1673098

OMICS. 2025 Oct 17. doi: 10.1177/15578100251387873. Online ahead of print.

ABSTRACT

Cancer is a disease with heterogenous molecular signatures that ought to be unpacked to achieve the overarching aim of precision oncology. A pan-cancer omics approach provides a systems science framework to explore shared and distinct mechanisms across cancers. We report here pan-cancer analyses of gene expression data from 17 cancers, for example, adrenocortical cancer, lung cancer, kidney cancer, and colorectal cancer, and 26 tissue types, using public datasets to construct disease-specific transcriptional networks. Using the hypergeometric test, 1005 microRNAs (miRNAs), 314 transcription factors (TFs), and 332 receptors were identified as regulatory molecules interacting with differentially expressed genes. Kyoto Encyclopedia of Genes and Genomes pathway analysis was performed to explore their functional roles. Accordingly, we found miR-124-3p, miR-6799-5p, and miR-7106-5p as common miRNAs; Specificity Protein 1 (SP1), RELA Proto-Oncogene, NF-κB Subunit (RELA), and Nuclear Factor Kappa B Subunit 1 (NFKB1) as shared TFs; Cyclin-Dependent Kinase 2 (CDK2), Histone Deacetylase 1 (HDAC1), and ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase (ABL1) as common receptors; and pathways in cancer, PI3K-Akt signaling, and p53 signaling as commonly enriched. Survival analysis in an independent dataset confirmed these findings: SP1 and NFKB1 were significant in 9 cancers, RELA in 6, whereas CDK2, HDAC1, and ABL1 were significant in 11, 10, and 10 cancers, respectively, out of the 17 cancers researched herein. In conclusion, these findings provide system-level insights on tumor heterogeneity and inform future cancer classification, for example, according to shared and distinct molecular signatures and development of therapies that might prove effective across several cancers. We underline that unpacking molecular signatures across multiple cancers also offers new prospects to move beyond the "One Drug, One Disease" paradigm of pharmaceutical innovation.

PMID:41111411 | DOI:10.1177/15578100251387873

Oral Oncol. 2025 Nov;170:107760. doi: 10.1016/j.oraloncology.2025.107760. Epub 2025 Oct 17.

ABSTRACT

Non-viral head and neck squamous cell carcinoma (HNSCC) has poor survival and high recurrence rates. Circulating tumor DNA (ctDNA) is a promising biomarker for understanding tumor biology, assessing treatment response, and monitoring disease progression. While extensively studied in virally mediated HNSCC, its role in non-viral HNSCC remains underexplored. This systematic review and meta-analysis consolidates evidence on the diagnostic, prognostic, and therapeutic value of ctDNA in non-viral HNSCC. A systematic search across Medline, PubMed, Embase, and the Cochrane Library identified 1,915 records, of which 47 were included. Data extraction followed PRISMA guidelines, with overall survival (OS), progression-free survival (PFS), and recurrence-free survival (RFS), pooled as hazard ratios (HRs) with 95% confidence intervals (CIs) using a fixed-effect model. Among 3,574 patients, the most common tumor sites were the oral cavity (35 %) and oropharynx (22 %), with the majority presenting with stage IVA/IVB disease (29 %). Pre-treatment ctDNA detection rates ranged from 50 % to 100 % (median: 83 %), while post-treatment detection rates varied between 28 % and 100 % (median: 48 %). ctDNA detected recurrence in 80 % of patients, with a median lead time of 4.6 months. ctDNA detection was significantly associated with worse OS (HR 10.26, 95 % CI 3.58-29.40; P < 0.0001). Residual ctDNA was strongly correlated with worse PFS (HR 7.32, 95 % CI 4.17-12.86; P < 0.00001) and RFS (HR 7.33, 95 % CI 2.75-19.58; P < 0.0001). ctDNA holds potential for improving diagnostic accuracy, monitoring progression, and predicting survival outcomes in non-viral HNSCC. However, further large-scale studies and standardized guidelines are needed for validation and clinical implementation.

PMID:41108912 | DOI:10.1016/j.oraloncology.2025.107760